Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xi Ding

Showing results (161-170 of 169) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 169 results.
Cell Reports. Medicine|October 16, 2024
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinomaXiong Zou, Xi Ding, Zheng-Kai Feng, et al.
Therapeutic Advances in Medical Oncology|July 21, 2022
Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective studyMeng-Xia Zhang, Ting Liu, Rui You, et al.
International Journal of Biological Macromolecules|March 18, 2026
Integrated expression of d-allulose 3-epimerase in Bacillus subtilis via the random integration systemLong-Tao Wang, Zun Tao, Yuan Zhang, et al.
Cell Reports. Medicine|November 11, 2023
Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trialSi-Yuan Chen, Xiao-Tong Duan, Hui-Feng Li, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2025
Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinomaSi-Yuan Chen, Xiao-Tong Duan, Rui-Ling Xie, et al.
NEJM Evidence|April 22, 2025
Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal CarcinomaPei-Yu Huang, Xu-Yin Chen, Xi Ding, et al.
BMJ (Clinical Research Ed.)|February 10, 2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trialRui You, Gui-Qiong Xu, Xi Ding, et al.
Cancer Research|December 15, 2023
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell CarcinomaYige Wu, Siqi Chen, Xiaolu Yang, et al.
Lancet (London, England)|February 26, 2023
Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialRui You, You-Ping Liu, Yu-Long Xie, et al.
Pageof 17

Showing results (161-170 of 169) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 169 results.
Cell Reports. Medicine|October 16, 2024
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinomaXiong Zou, Xi Ding, Zheng-Kai Feng, et al.
Therapeutic Advances in Medical Oncology|July 21, 2022
Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective studyMeng-Xia Zhang, Ting Liu, Rui You, et al.
International Journal of Biological Macromolecules|March 18, 2026
Integrated expression of d-allulose 3-epimerase in Bacillus subtilis via the random integration systemLong-Tao Wang, Zun Tao, Yuan Zhang, et al.
Cell Reports. Medicine|November 11, 2023
Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trialSi-Yuan Chen, Xiao-Tong Duan, Hui-Feng Li, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2025
Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinomaSi-Yuan Chen, Xiao-Tong Duan, Rui-Ling Xie, et al.
NEJM Evidence|April 22, 2025
Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal CarcinomaPei-Yu Huang, Xu-Yin Chen, Xi Ding, et al.
BMJ (Clinical Research Ed.)|February 10, 2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trialRui You, Gui-Qiong Xu, Xi Ding, et al.
Cancer Research|December 15, 2023
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell CarcinomaYige Wu, Siqi Chen, Xiaolu Yang, et al.
Lancet (London, England)|February 26, 2023
Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialRui You, You-Ping Liu, Yu-Long Xie, et al.
Pageof 17